Targeting the mammalian target of rapamycin (mTOR) protein is a promising strategy for cancer therapy. The mTOR kinase functions in two complexes, TORC1 (target of rapamycin complex-1) and TORC2 (target of rapamycin complex-2); however, neither of these complexes is fully inhibited by the allosteric inhibitor rapamycin or its analogs. We compared rapamycin with PP242, an inhibitor of the active site of mTOR in both TORC1 and TORC2 (hereafter referred to as TORC1/2), in models of acute leukemia harboring the Philadelphia chromosome (Ph) translocation. We demonstrate that PP242, but not rapamycin, causes death of mouse and human leukemia cells. In vivo, PP242 delays leukemia onset and augments the effects of the current front-line tyrosine kinase inhibitors more effectively than does rapamycin. Unexpectedly, PP242 has much weaker effects than rapamycin on the proliferation and function of normal lymphocytes. PI-103, a less selective TORC1/2 inhibitor that also targets phosphoinositide 3-kinase (PI3K), is more immunosuppressive than PP242. These findings establish that Ph + transformed cells are more sensitive than normal lymphocytes to selective TORC1/2 inhibitors and support the development of such inhibitors for leukemia therapy.
The PI3K-AKT-mTOR signaling axis is central to the transformed phenotype of most cancer cells 1 . PI3K is a lipid kinase whose products mediate membrane assembly of signaling complexes downstream of activated tyrosine kinases and the small GTPase Ras. AKT serine-threonine kinases are activated in a PI3K-dependent manner to phosphorylate numerous substrates, thereby promoting cell growth, proliferation and survival 2 . Most tumor cells bear mutations that increase PI3K-AKT-mTOR signaling output 1, 3 , and activation of this pathway has been linked to chemoresistance in a variety of clinical settings 4, 5 . Therefore, priority has been given to the development of anticancer agents targeting PI3K, AKT or downstream enzymes such as mTOR 6 . However, this signaling network mediates essential physiological functions and is subject to complex cross-talk and feedback, which has complicated efforts to identify an optimal pharmacological profile to achieve effective and selective killing of cancer cells.
The mTOR kinase is present in two cellular protein complexes, TORC1 and TORC2, which have distinct subunit composition, substrates and mechanisms of activation (Fig. 1a) 7, 8 . The best-known substrates of TORC1 are S6 kinase (S6K) and 4E-BP1 (eukaryotic initiation factor 4E-binding protein-1); the main substrates of TORC2 are AKT and related kinases. Rapamycin (sirolimus) and its analogs, such as RAD001 (everolimus) and CCI-779 (temsirolimus), suppress mTOR activity through an allosteric mechanism that acts at a distance from the ATPcatalytic binding site 6, 9, 10 . Members of this class of mTOR inhibitor have profound immunomodulatory activity 11, 12 but have achieved limited success as anticancer agents 9 . Mechanistically, rapamycin has two main drawbacks (Fig. 1a) . First, the drug suppresses TORC1-mediated S6K activation, thereby blocking a negative feedback loop, but does not acutely inhibit TORC2. In many cancer cells, this leads to elevated PI3K-AKT signaling and promotes cell survival 10 . Second, rapamycin is an incomplete inhibitor of TORC1, reducing phosphorylation of 4E-BP1 only partially in most cell contexts [13] [14] [15] [16] [17] .
A promising approach to overcome these limitations is through ATPcompetitive 'active-site' mTOR inhibitors. One strategy has been to use small-molecule TORC1/2 inhibitors that also inhibit PI3K lipid kinases (Fig. 1a) 6 . One such compound, PI-103, is more potent than rapamycin in mouse models of leukemia and in primary human leukemia colony assays [18] [19] [20] [21] . However, the clinical therapeutic efficacy and tolerability of such dual PI3K-mTOR inhibitors remain to be established. Recently, four independent groups reported the discovery and characterization of selective ATP-competitive TORC1/2 inhibitors [14] [15] [16] [17] . Active-site mTOR inhibitors strongly suppress 4E-BP1 phosphorylation and reduce phosphorylation of TORC2 substrates, including AKT (Fig. 1a) , without strongly inhibiting PI3K [14] [15] [16] [17] . Here we report a comparison of the effects of rapamycin and a selective TORC1/2 inhibitor, PP242, in models of leukemia and on normal lymphocyte function. We demonstrate that PP242 has potent cytotoxic activity against leukemia cells and enhances the efficacy of the tyrosine kinase inhibitors (TKIs) imatinib and dasatinib in Ph + acute leukemia models. The effects of PP242 are similar to those of pan-PI3K-TORC1/2 inhibitors but stronger than those of volume 16 | number 2 | february 2010 nature medicine rapamycin. We also report an unexpected reversal of potency, such that rapamycin produces much stronger immunosuppression than PP242 in a set of in vitro and in vivo assays of adaptive immune function. At doses that show therapeutic effects in leukemia models, the pan-PI3K-TORC1/2 inhibitor PI-103 is also more immunosuppressive than PP242. Thus, selective TORC1/2 inhibitors might achieve a favorable balance of efficacy and tolerability that is superior to other approaches targeting this pathway in cancer.
RESULTS

Selective TORC1/2 inhibition causes death of BCR-ABL + cells
The structure and selectivity of the pyrazolopyrimidine compound PP242 have been reported previously 14 , and further drug-related information is provided in Supplementary Table 1. We tested the efficacy of PP242 in models of Ph + B precursor acute lymphoblastic leukemia (B-ALL), a subtype of leukemia initiated by the BCR-ABL oncogene that arises from the Philadelphia chromosome translocation 22, 23 . When mouse bone marrow cells are infected with a retrovirus expressing human p190 BCR-ABL (p190 is the isoform of BCR-ABL most commonly detected in Ph + B-ALL), transformed progenitor B cell lines (termed p190 cells) emerge that initiate aggressive B-ALL upon transfer to recipient mice 19, 24 . We monitored the proliferation and survival of p190 cells treated with mTOR inhibitors in comparison to the TKIs imatinib and dasatinib that are currently used in the clinic to suppress BCR-ABL tyrosine kinase activity (Fig. 1b and Supplementary Table 2) . Using a colorimetric assay (MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) conversion), we observed that both imatinib and dasatinib fully suppressed cell growth, as expected ( Fig. 1b and Supplementary  Table 2 ). Rapamycin had antiproliferative effects (50% growth The number of viable mouse p190, human SUP-B15 or human K562 cells after 48 h of treatment with the indicated inhibitors, as determined by the MTS conversion assay (n = 3-9 independent experiments, error bars omitted for clarity). BM, bone marrow. (c) DNA content, as measured by flow cytometry, in p190 cells cultured for 24 h with the indicated inhibitors. Representative of three independent experiments. (d-f) Anticlonogenic effects of TORC1/2 and pan-PI3K-TORC1/2 inhibitors with and without dasatinib in primary Ph + leukemias. Purified bone marrow or peripheral blood from untreated, newly diagnosed individuals with Ph + B-ALL (n = 8) (d), relapsed or refractory Ph + B-ALL (n = 6) (e) or imatinib-resistant blast crisis (BC)-CML (n = 4 for lymphoid BC-CML and n = 1 for myeloid BC-CML) (f) were assessed for colony formation potential in MethoCult cultures with dasatinib (DA; 5 nM) alone or in combination with increasing concentrations (20 or 200 nM) of rapamycin (Rap), PP242 or BEZ-235. Colony numbers were normalized to the vehicle control for each human specimen and reported as the mean ± s.d., with n = total number of individual specimens as listed above, each tested once (*P < 0.05, **P < 0.01, #P < 0.001, repeated-measures analysis of variance (ANOVA), measured versus the vehicle control (Ctrl), except where indicated by brackets). Supplementary Table 4 contains a more detailed description of the human leukemic samples. Table 2 ). Cell cycle analysis confirmed that TORC1/2 inhibitors and pan-PI3K-TORC1/2 inhibitors caused both cell cycle arrest and death, whereas rapamycin was primarily cytostatic (Fig. 1c) . We also observed a greater antiproliferative potency of PP242 relative to rapamycin in a panel of solid tumor cell lines carrying either PI3K gain of function or PTEN (phosphatase and tensin homolog) loss of function mutations (Supplementary Table 3) , indicating a generally stronger anticancer effect of TORC1/2 inhibitors; this is in agreement with a recently reported study of TORC1/2 inhibitors in solid tumor lines 17 . The GI 50 of PI-103 was consistently at least two times higher than that of PP242 in these assays (Supplementary Tables 2a and 3) .
PP242 enhances the antileukemic effects of TKIs in vitro
Imatinib provides poor long-term survival in Ph + B-ALL 27, 28 . Relapse of both Ph + B-ALL and blast crisis CML are often due to mutations in the BCR-ABL kinase domain that cause resistance to imatinib. Secondgeneration ABL TKIs such as dasatinib suppress the activity of some imatinib-resistant BCR-ABL variants (for example, those with Y253H or E255K mutations) but not others (those with T315I mutations). Targeting signaling pathways downstream of BCR-ABL, such as with TORC1/2 inhibition, might overcome this resistance 29, 30 . Our observation that PP242 causes apoptosis (Fig. 1c) further suggested that TORC1/2 inhibitors might overcome resistance to TKIs and also synergize with TKIs to kill leukemia cells. Indeed, transformation of mouse bone marrow cells with BCR-ABL was inhibited to a similar extent by PP242 when comparing its effects on wild-type p190 BCR-ABL or mutants (Y253H, E255K or T315I) (Supplementary Fig. 1a) . Furthermore, PP242 strongly synergized with imatinib in suppressing the growth of cells expressing wildtype p190, similar to the potency achieved with BEZ235 and imatinib ( Supplementary Fig. 1b and Supplementary Table 2 ). This synergistic effect of PP242 with imatinib was superior to that of rapamycin with imatinib ( Supplementary Fig. 1b and Supplementary Table 2) .
We further tested the effects of PP242 alone or when combined with ABL inhibitors on primary human Ph + B-ALL cells, including samples from newly diagnosed cases and from drug-resistant relapses (Fig. 1d,e and Supplementary Table 4 for subject characteristics). For these experiments, we used dasatinib to inhibit BCR-ABL, as this agent is emerging as a favored TKI for Ph + B-ALL treatment, either as a monotherapy or combined with chemotherapy 27, 31 . PP242 significantly reduced colony formation in samples of newly-diagnosed Ph + B-ALL and augmented the effect of dasatinib in samples derived from subjects who had relapsed after combination chemotherapy with imatinib ( Fig. 1d,e) . BEZ235 had a similar potency to PP242 when tested alone or with dasatinib, whereas rapamycin had a lesser effect in these sample groups and did not augment dasatinib efficacy (Fig. 1d,e) . In five samples obtained from cases of blast crisis-stage Ph + CML, rapamycin was equally effective as PP242 or BEZ-235 (Fig. 1f) .
PP242 and rapamycin have distinct effects on TORC1/2 outputs
In fibroblasts and solid tumor cell lines, active-site mTOR inhibitors suppress rapamycin-resistant outputs of TORC1 and TORC2 (refs. 14-17). Similarly, in p190 cells, PP242 suppressed phosphorylation a r t i c l e s of the Ser473 residue of Akt, a TORC2 phosphorylation site, whereas rapamycin treatment caused an increase over time in Ser473 phosphorylation as well as in phosphorylation of the PDK1 (phosphoinositide-dependent kinase-1) site Thr308 (Fig. 2a,b) . Although both drugs effectively suppressed phosphorylation of the ribosomal S6 protein (rS6), only PP242 decreased phosphorylation of 4E-BP1 (Fig. 2a,b) . These distinct phosphoprotein signatures of PP242 and rapamycin remained apparent when the drugs were combined with clinically achievable concentrations of ABL kinase inhibitors (Fig. 2b) ; p4E-BP1 and pAkt amounts were more effectively suppressed by treatment with TKIs plus PP242 as compared to treatment with TKIs plus rapamycin. Notably, TKIs alone did not fully suppress TORC1/2 signaling (Fig.  2b) , as has been observed previously in other BCR-ABL-driven cell models 32, 33 . We obtained similar results with SUP-B15 and K562 cells ( Fig. 2c-f) . Cap-dependent messenger RNA translation is facilitated by TORC1-mediated phosphorylation of 4E-BP1, which releases this inhibitory protein from eukaryotic initiation factor 4E (eIF4E) (refs. 7,8) . PP242 treatment of p190 cells increased binding of 4E-BP1 to eIF4G with a concomitant decrease in binding of 4E-BP1 to eIF4E, whereas rapamycin had little effect (Supplementary Fig. 2) . Although PP242 at high concentrations can inhibit PI3K enzymes in vitro 14 , the drug did not alter cellular production of the PI3K product phosphatidylinositol-3,4,5-trisphosphate (PIP 3 ) in p190 cells (Fig. 3a) . In contrast, rapamycin treatment increased PIP 3 production (Fig. 3a) . It is possible that PP242 counteracts feedback activation of PI3K through its ability to weakly inhibit PI3K enzymes at concentrations that fully inhibit TORC1/2.
To assess TORC2 function, we examined the phosphorylation and localization of forkhead box O (Foxo) transcription factors, which are substrates of both Akt and serum-and glucocorticoid-induced kinase downstream of TORC2 (refs. 34,35) . PP242, but not rapamycin, reduced Foxo phosphorylation on Akt consensus sites (Fig. 2a,c-f ) and caused nuclear accumulation of Foxo1 in p190 cells correlating with greater inhibition of cell cycling (Fig. 3b) . PP242, but not rapamycin, also decreased mTOR autophosphorylation on Ser2481, phosphorylation of the Akt substrates glycogen synthase kinase-3 (GSK3) and proline-rich Akt substrate of 40 kDa (PRAS40) and phosphorylation of the serum-and glucocorticoid-induced kinase-1 substrate N-myc downstream regulated gene-1 (NDRG1), all indicators of TORC2 activity [14] [15] [16] [17] 36, 37 (Fig. 2a) . Thus, PP242 blocked all TORC1 and TORC2 outputs tested without altering PIP 3 levels. PP242 also seemed to increase autophagy more than did rapamycin in p190 cells, as indicated by accumulation of LC3-II (Fig. 3c) .
PP242 suppresses leukemia better than rapamycin in vivo
To compare the pharmacological characteristics and antileukemic efficacy of mTOR inhibitors alone or in combination with TKIs in vivo, we used three models: a mouse model of p190 BCR-ABL pre-B lymphoid leukemia transplanted into syngeneic recipients; a bioluminescent xenograft model of human SUP-B15 cells stably expressing luciferase and transplanted into immunocompromised nonobese diabetic, severe combined immunodeficient, interleukin-2 receptor-γ-knockout mice (NSG mice 38 ); and a xenograft model in which four independent leukemia specimens were transplanted into NSG mice.
The mouse p190 model produces reproducible engraftment and fatal leukemia in recipients that are either irradiated or nonirradiated; the disease in these mice has pathologic features resembling those of human B-ALL 24 . This model is convenient for both survival measurements and pharmacodynamic monitoring. In this model, 
short-term oral dosing with PP242 significantly reduced leukemic burden in the spleen and bone marrow in a dose-dependent manner, which correlated with inhibition of cell cycle progression and induction of apoptosis in the leukemia cells (Fig. 4a-d and Supplementary  Figs. 3-5) . These effects were associated with inhibition of TORC1 and TORC2 substrate phosphorylation and a smaller leukemic cell size ( Fig. 4d and Supplementary Fig. 3 ). PI-103 (60 mg per kg body weight twice per day (b.i.d.)) treatment significantly potentiated the effects of imatinib in this model (Fig. 4e) , similarly to our previous findings 19 . In contrast, mice treated with rapamycin showed no significant reduction in leukemic burden ( Fig. 4e and Supplementary   Fig. 4) . This was not due to poor bioavailability, because rapamycin treatment caused strong inhibition of rS6 phosphorylation ( Supplementary Fig. 4 ) and was severely immunosuppressive at this dose, as discussed below. We also detected decreased phosphorylation of Akt on Ser473 in rapamycin-treated mice, consistent with reports that rapamycin can inhibit assembly of TORC2 after extended exposure to the drug 39 .
In a long-term survival study, oral dosing of PP242 (30 and 60 mg per kg body weight) significantly delayed the onset of leukemia (Fig. 4f) . Rapamycin had no effect on its own in this setting but augmented the protective effect of a suboptimal dose of imatinib (150 mg per kg body a r t i c l e s weight), as previously reported 40 . The combination of PP242 with imatinib provided the greatest survival benefit, with two of five mice showing minimal disease (2-20% in the bone marrow) one month after initiation of treatment ( Fig. 4f and Supplementary Fig. 3b ).
In the xenograft models, we focused on the ability of PP242 to enhance the efficacy of dasatinib, an emerging standard of care for treatment of patients with Ph + B-ALL. This experimental approach was motivated in part by the greater efficacy of combination treatments in human Ph + B-ALL colony assays (Fig. 1) and also by the likelihood that new active-site mTOR inhibitors will be tested clinically in combination with approved TKIs. The SUP-B15-luciferase xenograft model allowed us to perform quantification of leukemia cell expansion over time using sequential bioluminescent imaging and to correlate these results with signaling differences observed in SUP-B15 cells treated with drug combinations in vitro (Fig. 2c,d ). We chose a daily dose of dasatinib reported to be efficacious in K562 xenografts (2.5 mg per kg body weight) 41 . This dose modestly delayed SUP-B15 expansion in vivo (Fig. 5a) , providing a useful system to test for improved efficacy of combination treatments. Although rapamycin enhanced the effect of dasatinib, leukemic burden continued to increase with this combination (Fig. 5a) . In contrast, the combination of dasatinib with PP242 caused regression of leukemic disease and prevented dissemination to the central nervous system (Fig. 5a) .
In xenograft experiments using primary human leukemia samples, we tested PP242 in combination with a higher dose of dasatinib (5 a r t i c l e s per kg body weight) that significantly suppressed expansion of some Ph + B-ALL samples (MD1 and MD3) but not others (MD4 and MD11) (Fig.  5b-h and Supplementary Fig. 6 ; Supplementary Table 4 contains subject characteristics). The combination of PP242 and dasatinib significantly decreased leukemia burden, leukemia cell cycling or both (Fig. 5b-h and Supplementary Fig. 6 ). Dasatinib combined with PP242 was more effective than dasatinib alone in a short-term (1-week) treatment study of sample MD1 and in a long-term (3-week) treatment study of sample MD3 (Fig. 5c,d,g ). Dasatinib plus PP242 caused apoptosis of human CD19 + cells in the bone marrow of xenograft recipients; concurrently, endogenous hematopoietic cells of the recipient mice showed recovery of cell cycling (Fig. 5c,d ,g-h and Supplementary Fig. 6b ). Sample MD4 (which carried the T315I mutated form of BCR-ABL) showed less proliferation in xenografted mice treated with dasatinib plus PP242 (Fig. 5e) , and although the leukemic burden in the bone marrow was not significantly affected, the spleen weight was reduced (Supplementary Fig. 6c ). For sample MD11, which showed dasatinib resistance in the bone marrow despite no detectable BCR-ABL mutations, a 2-week treatment with dasatinib plus PP242 lowered leukemic burden, proliferation and spleen weight ( Fig. 5h and Supplementary Fig. 6c ). The greater response of MD11 relative to MD4 might have resulted from a difference in leukemic burden at the start of treatment, the different lengths of treatment or leukemia-specific genetic differences. We did not observe drug-related toxicity in mice at therapeutic doses of PP242 ( Supplementary Fig. 6d and data not shown).
TORC1/2 inhibitors are less immunosuppressive than rapamycin
Rapamycin and its analogs are immunosuppressive and myelosuppressive 42 . In contrast, in mice treated with PP242 we observed a highly selective response of leukemia cells compared to normal hematopoietic cells. PP242 prevented infiltration of the spleen and lymph nodes by p190 cells while largely preserving the normal splenic architecture and T cell abundance in lymphoid organs ( Supplementary Figs. 4 and 5) . In contrast, rapamycin did not fully preserve splenic architecture or T cell counts in the p190 model ( Supplementary Figs. 4 and 5b) . PP242 in combination with (Fig. 5c,d,g and Supplementary Fig. 6b) . In human hematopoietic colony-forming assays (Fig. 6a) , rapamycin was myelosuppressive at much lower concentrations than PP242. The dual PI3K-mTOR inhibitor PI-103 had comparable effects to PP242 in these colony-forming assays (Fig. 6a) . Considering that the GI 50 of PI-103 in cancer cell lines was twofold to sevenfold greater than that of PP242, it was striking that PI-103 showed a much greater hematotoxicity at a dose (2 µM) that was twofold higher than the highest dose tested of PP242 (1 µM) (Fig. 6a) . We also observed that p190 cell-transplanted mice treated with imatinib and a therapeutic dose of PI-103 (60 mg per kg body weight b.i.d.), but not imatinib plus a therapeutic dose of PP242 (60 mg per kg body weight once daily (q.d.)), had reduced cycling of endogenous bone marrow cells (Fig. 4e) .
PP242 showed consistently weaker effects than rapamycin in assays of adaptive immune function. Rapamycin (1-10 nM) strongly suppressed ex vivo B and T cell proliferation (Fig. 6b-d and Supplementary Fig. 7) . In contrast, PP242 had little effect at 1-10 nM, with increasing effects at 100 nM and 1 µM, the latter far exceeding its effective concentration for inhibiting growth in leukemia cell lines (Fig. 1b) . The reduced antiproliferative potency of PP242 in primary lymphocytes compared to leukemia cells was not due to differences in its effects on TORC1/2 signaling, as the compound inhibited phosphorylation of Akt, 4E-BP1 and rS6 (Supplementary Fig. 7c ) at concentrations similar to those found to be effective in p190 cells (Fig. 2a,b) . PP242 also decreased the size of activated T cells, which we also observed in PP242-treated leukemia cells (Supplementary Fig. 3 ) and can be considered a surrogate readout for TORC1 inhibition (Fig. 6d) . As observed in human hematopoietic colony assays, PI-103 suppressed normal B cell proliferation much more strongly than did PP242 when tested at a twofold higher concentration (Fig. 6c) . Another pan-PI3K-TORC1/2 inhibitor, BEZ-235, suppressed T cell proliferation more strongly than did PP242 when tested at the same concentration ( Fig. 6d and Supplementary Fig. 7b ). Similarly to PP242, the TORC1/2 inhibitor Ku-0063794 had little effect on B cell proliferation at a concentration of 100 nM (Fig. 6c) and partially inhibited the response at 1 µM (data not shown).
To compare the effects of PP242 and rapamycin on adaptive immunity in vivo, we measured antibody responses to the CD4 + T cell-dependent antigen nitrophenyl-ovalbumin (NP-OVA). We treated mice orally with PP242 (60 mg per kg body weight), a dose that achieved rapid leukemic clearance in other experiments (Fig. 4 and 5) or with rapamycin (7.5 mg per kg body weight) starting 1 day before immunization. Whereas rapamycin strongly lowered nitrophenyl-specific antibody titers, PP242 had little or no effect (Fig. 6e) . These patterns were reflected in the percentage of B cells with a germinal center phenotype (Fig. 6f) . Furthermore, rapamycin treatment lowered the percentages of total T and B cells in the spleen, whereas PP242 did not (Fig. 6g) . In a separate experiment, we tested PI-103 at 10, 30 and 60 mg per kg body weight b.i.d. Although PI-103-treated mice developed nitrophenyl-specific antibody titers that were equivalent to those in vehicle-or PP242-treated mice (Fig. 6e) , PI-103 reduced the fraction of B cells with a germinal center phenotype (Fig. 6f) and lowered the percentages of total splenic B and T cells (Fig. 6g) . PI-103 also caused a dose-dependent displacement of marginal zone B cells ( Supplementary  Fig. 8 ), a surrogate readout for PI3K (p110δ) inhibition 43 .
DISCUSSION
We show here that a selective, active-site mTOR kinase inhibitor has potent antileukemic effects in vitro and in vivo, while leaving lymphocyte function largely intact. Active-site inhibition of TORC1/2 addresses rapamycin-resistant TORC1 outputs and prevents activation of AKT resulting from feedback regulation (Fig. 1a) . TORC1/2 inhibition caused selective apoptosis of leukemic cells and also synergized with clinically relevant TKIs in assays of both mouse and human leukemic expansion. A likely mechanism is that the PI3K-mTOR pathway is sustained by cytokines and serum factors even when BCR-ABL kinase activity is inhibited. These findings support the importance of TORC1/2 as a druggable target downstream of BCR-ABL in a disease in which resistance to TKIs develops rapidly. TORC1/2 inhibitors might be particularly effective when used with current induction regimens consisting of dasatinib with or without chemotherapy for treating Ph + B-ALL .
Whereas PP242 is toxic to leukemia cells, normal hematopoietic cells and mature lymphocytes survive in mice treated with therapeutic doses. Moreover, lymphocyte function shows an inverse pattern of drug sensitivity relative to leukemia cells, with rapamycin having more potent suppressive effects than PP242. The finding that pharmacological TORC1/2 inhibition is tolerated by the adaptive immune system was unexpected, considering that complete deletion of the gene encoding mTOR (Mtor) in mouse T cells has more severe effects on proliferation 44 . One possibility is that mTOR has a noncatalytic scaffolding function that is abolished by gene deletion or rapamycin treatment but not by the active-site kinase inhibitor. Another possibility is that PP242 does not provide sustained blockade of mTOR kinase activity through a dosing regimen that achieves therapeutic antileukemic effects; temporary inhibition of mTOR signaling outputs could be more detrimental to cancer cells, in which transient signaling interruption can commit the cell irreversibly to death through an effect termed 'oncogenic shock' 45 . At higher concentrations of PP242, lymphocyte proliferation was strongly suppressed in vitro. Of note, mice heterozygous for an allele of Mtor encoding a kinase-dead version of mTOR show normal lymphocyte proliferation 46 , supporting the idea that partial or temporary TORC1/2 kinase inhibition is tolerated by normal lymphocytes.
A key question is whether selective TORC1/2 inhibitors provide advantages over pan-PI3K-TORC1/2 pathway inhibitors. PI3K has numerous roles in cell survival, differentiation, metabolism and migration, some of which are independent of AKT and mTOR 1, 47 . Our data suggest that whereas TORC1/2 and pan-PI3K-TORC1/2 inhibitors both have antileukemic efficacy, the pan-PI3K-TORC1/2 inhibitors cause greater immune suppression. When we tested PI-103 at a twofold higher concentration than PP242, given the consistently twofold higher GI 50 of PI-103 in cancer cell lines, we observed greater suppression of hematopoietic colony formation and B cell proliferation. In vivo treatment of mice with PI-103 at concentrations that had antileukemic effects also lowered the abundance of key lymphocyte subsets that were unaffected by treatment with PP242. A recent report also found that PI-103 lowers lymphocyte numbers in vivo and showed that PI-103 suppresses immune rejection of melanoma xenografts 48 . It remains to be seen whether pan-PI3K-TORC1/2 inhibitors will provide an acceptable therapeutic window in humans. Our data indicate that selective TORC1/2 inhibition is an attractive alternative approach that provides equivalent antileukemic efficacy as pan-PI3K-TORC1/2 inhibitors while maintaining PI3K activity.
Overall, these findings provide encouragement for further preclinical and clinical studies of selective active-site mTOR inhibitors in cancer. Given the efficacy of PP242 when combined with dasatinib in Ph + B-ALL xenografts, therapy that combines TORC1/2 kinase inhibitors with TKIs that target other oncogenic 'driving' mutations may improve treatment outcomes in other leukemias and in epithelial malignancies.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nm/.
